Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

At ARVO 2026, Ikarovec presented 4 posters showcasing its bicistronic platform that combines neuroprotection and complement modulation.

  • By

  • Katie Binley, PhD

  • May 1, 2026

  • 3 min

Share

Clinical Scorecard: Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

At a Glance

CategoryDetail
ConditionGeographic Atrophy (GA)
Key MechanismsNeuroprotection and complement modulation
Target PopulationPatients with retinal degenerative diseases, specifically GA
Care SettingClinical research and gene therapy development

Key Highlights

  • IKAR-001 co-expresses PEDF for neuroprotection and soluble CD46 for complement modulation.
  • Current single pathway therapies for GA show modest effects and inconsistent improvements in visual function.
  • Neuroprotection is critical for achieving meaningful functional outcomes in GA treatment.
  • Next-generation gene therapies can target multiple pathways simultaneously.
  • Clinical data shows significant slower decline in visual acuity with neuroprotective gene therapy.

Guideline-Based Recommendations

Diagnosis

  • Assess visual function and anatomical changes in patients with GA.

Management

  • Consider dual-pathway gene therapies for comprehensive treatment of GA.

Monitoring & Follow-up

  • Regularly evaluate visual acuity and foveal sensitivity in treated patients.

Risks

  • Potential for modest effects with current single pathway therapies.

Patient & Prescribing Data

Individuals diagnosed with geographic atrophy and other retinal diseases.

IKAR-001 aims to provide both anatomical and functional benefits through a dual-pathway approach.

Clinical Best Practices

  • Utilize gene therapies that address multiple pathways for enhanced treatment outcomes.
  • Incorporate neuroprotective strategies in the management of retinal diseases.

Related Resources & Content

Original Source(s)

Dual-Pathway Gene Therapy Targets Multiple Drivers in Retinal Disease

  • by Katie Binley, PhD

  • May 1, 2026

Related Content

Five Years of Real World Ophthalmology

Lisa Nijm, MD, reflects on Real World Ophthalmology's growth and previews upcoming opportunities for young ophthalmologists to learn, connect, and advance their careers.

Reflections on Lumenis Accelerate from Laura Periman, MD

Optometric Management caught up with Laura Periman, MD, at the Lumenis Accelerate Owner’s Summit in Chicago on August 28 to discuss what attendees could take away from the event, both in clinical pearls and workflows and in practice management lessons.

  • September 1, 2026

  • 4 min
Dead bag syndrome may present asymmetrically

Spontaneous posterior capsular rupture affected both eyes years following uncomplicated cataract surgery, but intraocular lens dislocation required surgery in only 1 eye.